The economic burden of oral squamous cell carcinoma in Australia

Katherine Pollaers, Ian Massingham, Peter L. Friedland, Camile S. Farah

Research output: Contribution to journalArticle

Abstract

Objectives: The financial burden of treatment for oral squamous cell carcinoma in Australia has never been reported, and there is a paucity of international data. Here, we report the direct costs of treatment of surgically resectable oral cancer in a tertiary public hospital in Australia over a 15-year period. Materials and Methods: Pathology department records, records of hospital attendance and hospital finance department records were interrogated to determine the direct costs of inpatient and outpatient treatment. Costs were adjusted using the total health price index so that all costs were equivalent to costings for the 2016/2017 financial year. Results: A total of 113 cases were identified as suitable for inclusion. Complete inpatient and outpatient hospital attendance and costing data for treatment and subsequent 2-year follow-up was available for 29 cases. The average total cost over the 2-year period was $92 958AUD (median $102 722, range $11 662-$181 512). On average, 92.8% of costs were incurred in the first year post-diagnosis. Inpatient costs, outpatient costs and total costs increased with increasing pathological cancer stage. Both 1- and 2-year post-diagnosis overall cost for patients with Stage 4 oral cavity cancer were more than two times greater than for patients with Stage 1 oral cancer. Conclusion: It is well documented that patients diagnosed at an earlier stage will have better survival outcomes, and it is assumed that the economic burden of their treatment will be less. We have shown that there is a direct correlation between cancer stage and cancer treatment cost. The findings provide clear economic support for oral cancer screening initiatives to detect earlier stage cancers, and the need to investigate novel techniques and technologies to detect oral squamous cell carcinoma early and reduce recurrence and mortality rates.

Original languageEnglish
JournalJournal Of Oral Pathology and Medicine
DOIs
Publication statusE-pub ahead of print - 27 Jun 2019

Fingerprint

Squamous Cell Carcinoma
Economics
Costs and Cost Analysis
Mouth Neoplasms
Inpatients
Outpatients
Health Care Costs
Neoplasms
Hospital Records
Public Hospitals
Hospital Departments
Therapeutics
Early Detection of Cancer
Tertiary Care Centers
Mouth
Pathology
Technology
Recurrence
Survival
Mortality

Cite this

@article{23f4be93876049b5a30133a2b5ff5646,
title = "The economic burden of oral squamous cell carcinoma in Australia",
abstract = "Objectives: The financial burden of treatment for oral squamous cell carcinoma in Australia has never been reported, and there is a paucity of international data. Here, we report the direct costs of treatment of surgically resectable oral cancer in a tertiary public hospital in Australia over a 15-year period. Materials and Methods: Pathology department records, records of hospital attendance and hospital finance department records were interrogated to determine the direct costs of inpatient and outpatient treatment. Costs were adjusted using the total health price index so that all costs were equivalent to costings for the 2016/2017 financial year. Results: A total of 113 cases were identified as suitable for inclusion. Complete inpatient and outpatient hospital attendance and costing data for treatment and subsequent 2-year follow-up was available for 29 cases. The average total cost over the 2-year period was $92 958AUD (median $102 722, range $11 662-$181 512). On average, 92.8{\%} of costs were incurred in the first year post-diagnosis. Inpatient costs, outpatient costs and total costs increased with increasing pathological cancer stage. Both 1- and 2-year post-diagnosis overall cost for patients with Stage 4 oral cavity cancer were more than two times greater than for patients with Stage 1 oral cancer. Conclusion: It is well documented that patients diagnosed at an earlier stage will have better survival outcomes, and it is assumed that the economic burden of their treatment will be less. We have shown that there is a direct correlation between cancer stage and cancer treatment cost. The findings provide clear economic support for oral cancer screening initiatives to detect earlier stage cancers, and the need to investigate novel techniques and technologies to detect oral squamous cell carcinoma early and reduce recurrence and mortality rates.",
keywords = "cost analysis, costs, economics, head and neck cancer, hospital, oral cancer, oral squamous cell carcinoma",
author = "Katherine Pollaers and Ian Massingham and Friedland, {Peter L.} and Farah, {Camile S.}",
year = "2019",
month = "6",
day = "27",
doi = "10.1111/jop.12907",
language = "English",
journal = "Journal of Oral Pathology & Medicine",
issn = "0904-2512",
publisher = "Wiley-Blackwell",

}

The economic burden of oral squamous cell carcinoma in Australia. / Pollaers, Katherine; Massingham, Ian; Friedland, Peter L.; Farah, Camile S.

In: Journal Of Oral Pathology and Medicine, 27.06.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The economic burden of oral squamous cell carcinoma in Australia

AU - Pollaers, Katherine

AU - Massingham, Ian

AU - Friedland, Peter L.

AU - Farah, Camile S.

PY - 2019/6/27

Y1 - 2019/6/27

N2 - Objectives: The financial burden of treatment for oral squamous cell carcinoma in Australia has never been reported, and there is a paucity of international data. Here, we report the direct costs of treatment of surgically resectable oral cancer in a tertiary public hospital in Australia over a 15-year period. Materials and Methods: Pathology department records, records of hospital attendance and hospital finance department records were interrogated to determine the direct costs of inpatient and outpatient treatment. Costs were adjusted using the total health price index so that all costs were equivalent to costings for the 2016/2017 financial year. Results: A total of 113 cases were identified as suitable for inclusion. Complete inpatient and outpatient hospital attendance and costing data for treatment and subsequent 2-year follow-up was available for 29 cases. The average total cost over the 2-year period was $92 958AUD (median $102 722, range $11 662-$181 512). On average, 92.8% of costs were incurred in the first year post-diagnosis. Inpatient costs, outpatient costs and total costs increased with increasing pathological cancer stage. Both 1- and 2-year post-diagnosis overall cost for patients with Stage 4 oral cavity cancer were more than two times greater than for patients with Stage 1 oral cancer. Conclusion: It is well documented that patients diagnosed at an earlier stage will have better survival outcomes, and it is assumed that the economic burden of their treatment will be less. We have shown that there is a direct correlation between cancer stage and cancer treatment cost. The findings provide clear economic support for oral cancer screening initiatives to detect earlier stage cancers, and the need to investigate novel techniques and technologies to detect oral squamous cell carcinoma early and reduce recurrence and mortality rates.

AB - Objectives: The financial burden of treatment for oral squamous cell carcinoma in Australia has never been reported, and there is a paucity of international data. Here, we report the direct costs of treatment of surgically resectable oral cancer in a tertiary public hospital in Australia over a 15-year period. Materials and Methods: Pathology department records, records of hospital attendance and hospital finance department records were interrogated to determine the direct costs of inpatient and outpatient treatment. Costs were adjusted using the total health price index so that all costs were equivalent to costings for the 2016/2017 financial year. Results: A total of 113 cases were identified as suitable for inclusion. Complete inpatient and outpatient hospital attendance and costing data for treatment and subsequent 2-year follow-up was available for 29 cases. The average total cost over the 2-year period was $92 958AUD (median $102 722, range $11 662-$181 512). On average, 92.8% of costs were incurred in the first year post-diagnosis. Inpatient costs, outpatient costs and total costs increased with increasing pathological cancer stage. Both 1- and 2-year post-diagnosis overall cost for patients with Stage 4 oral cavity cancer were more than two times greater than for patients with Stage 1 oral cancer. Conclusion: It is well documented that patients diagnosed at an earlier stage will have better survival outcomes, and it is assumed that the economic burden of their treatment will be less. We have shown that there is a direct correlation between cancer stage and cancer treatment cost. The findings provide clear economic support for oral cancer screening initiatives to detect earlier stage cancers, and the need to investigate novel techniques and technologies to detect oral squamous cell carcinoma early and reduce recurrence and mortality rates.

KW - cost analysis

KW - costs

KW - economics

KW - head and neck cancer

KW - hospital

KW - oral cancer

KW - oral squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85068126141&partnerID=8YFLogxK

U2 - 10.1111/jop.12907

DO - 10.1111/jop.12907

M3 - Article

JO - Journal of Oral Pathology & Medicine

JF - Journal of Oral Pathology & Medicine

SN - 0904-2512

ER -